This page lists our patient-driven research studies into ROS1+ cancers. ROS1+ cancer is a rare cancer, occurring in a small percentage of lung, gastric, and ovarian cancers, as well as in melanoma, glioblastoma, cholangiocarcinoma, angiosarcoma, and melanoma. The number of patients available for study at any one cancer center are limited. As ROS1 patients, we can accelerate research in ways no one else can. Through social media and online patient communities, ROS1 patients are helping researchers discover risk factors for ROS1 cancer, the biology of ROS1 cancer, and hopefully new treatments for our disease.
Open to all patients with ROS1+ solid tumors.
Goal: understand what drives tumor formation, therapeutic response, and acquired therapeutic resistance in ROS1 cancer
Cell Line Initiative Principal Investigator: Robert C. Doebele, MD, PhD, University of Colorado
PDX Study Principal Investigator: Christine Lovly, MD, PhD, Vanderbilt University Medical Center
Sponsor: Addario Lung Cancer Medical Institute
Start Date: April 13, 2018
Close Date: ongoing
Results: see data on our ROS1 Cancer Model Project page
To Participate: If you have a biopsy or surgical procedure coming up, call Nurse Alicia at 866-988-ROS1 (866-988-7671) or visit alcmi.net/research/ros1-cell-line-study (cell line study) or alcmi.net/research/ros1-pdx-study (PDX study).
Short Polls across the ROS1der Cohort
The ROS1ders conduct short, informal polls among ROS1+ patients using Survey Monkey, and share the de-identified results on this website in hopes of accelerating research in and treatments for ROS1+ cancers.
Goal: determine how many ROS1der patients might be available to participate in research, and whether they are willing to participate in research
Start date: November 2016
Close date: ongoing
Results: posted at http://wp.me/P6JQMq-iH and updated periodically
To Participate: go to this webpage https://www.surveymonkey.com/r/N8S5P5K